{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T21:05:28Z","timestamp":1769288728332,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04253-w","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:44:00Z","timestamp":1766087040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gender influences prognosis of classical BCR::ABL1 negative myeloproliferative neoplasms: a retrospective cohort study"],"prefix":"10.1007","volume":"17","author":[{"given":"Yanan","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuebo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zunmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"4253_CR1","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1182\/blood.2022017416","volume":"141","author":"J How","year":"2023","unstructured":"How J, Garcia JS, Mullally A. Biology and therapeutic targeting of molecular mechanisms in MPNs. Blood. 2023;141:1922\u201333.","journal-title":"Blood"},{"key":"4253_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-025-01235-7","volume":"15","author":"J Thiele","year":"2025","unstructured":"Thiele J, Kvasnicka HM, Gianelli U, Arber DA, Tefferi A, Vannucchi AM, et al. Evolution of WHO diagnostic criteria in classical myeloproliferative neoplasms compared with the international consensus classification. Blood Cancer J. 2025;15:31.","journal-title":"Blood Cancer J"},{"key":"4253_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ajh.24221","volume":"91","author":"A Tefferi","year":"2016","unstructured":"Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol. 2016;91:50\u20138.","journal-title":"Am J Hematol"},{"key":"4253_CR4","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313. quiz 615.","journal-title":"Blood"},{"key":"4253_CR5","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia Vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.","journal-title":"Blood Cancer J"},{"key":"4253_CR6","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874\u201381.","journal-title":"Leukemia"},{"key":"4253_CR7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 world health Organization-defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment. Blood. 2012;120:1197\u2013201.","journal-title":"Blood"},{"key":"4253_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia Vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"4253_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International working group for myeloproliferative neoplasms research and Treatment). Blood. 2010;115:1703\u20138.","journal-title":"Blood"},{"key":"4253_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310\u201318.","journal-title":"J Clin Oncol"},{"key":"4253_CR11","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32:1631\u201342.","journal-title":"Leukemia"},{"key":"4253_CR12","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","volume":"4","author":"T Karantanos","year":"2020","unstructured":"Karantanos T, Chaturvedi S, Braunstein EM, Spivak J, Resar L, Karanika S, et al. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020;4:2567\u201376.","journal-title":"Blood Adv"},{"key":"4253_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia Vera and essential thrombocythemia. Am J Med. 2004;117:755\u201361.","journal-title":"Am J Med"},{"key":"4253_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41375-023-02068-8","volume":"38","author":"M Ozga","year":"2024","unstructured":"Ozga M, Nicolet D, Mr\u00f3zek K, Yilmaz AS, Kohlschmidt J, Larkin KT, et al. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024;38:45\u201357.","journal-title":"Leukemia"},{"key":"4253_CR15","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1200\/JCO-24-01487","volume":"42","author":"MA Richard","year":"2024","unstructured":"Richard MA, Yan C, Chen Y, Gibson CJ, Kalra R, Bosworth A, et al. Sex-based differences in risk of therapy-related myeloid neoplasms. J Clin Oncol. 2024;42:3739\u201350.","journal-title":"J Clin Oncol"},{"key":"4253_CR16","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/S2352-3026(22)00323-4","volume":"10","author":"M Giulia","year":"2023","unstructured":"Giulia M, Matteo B, Erica T, Ana AP, Annika K, Arnan S, et al. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. Lancet Haematol. 2023;10:e117\u201328.","journal-title":"Lancet Haematol"},{"key":"4253_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11739-011-0634-3","volume":"7","author":"R Landolfi","year":"2012","unstructured":"Landolfi R, Di Gennaro L, Nicolazzi MA, Giarretta I, Marfisi R. Marchioli. Polycythemia vera: gender-related phenotypic differences. Intern Emerg Med. 2012;7:509\u201315.","journal-title":"Intern Emerg Med"},{"key":"4253_CR18","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ajh.24882","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, et al. Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. Am J Hematol. 2017;92:1193\u201397.","journal-title":"Am J Hematol"},{"key":"4253_CR19","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","volume":"32","author":"M Nicolosi","year":"2018","unstructured":"Nicolosi M, Mudireddy M, Lasho TL, Hanson CA, Ketterling RP, Gangat N, et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia. 2018;32:1254\u201358.","journal-title":"Leukemia"},{"key":"4253_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-018-0128-x","volume":"8","author":"D Barraco","year":"2018","unstructured":"Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, et al. Gender effect on phenotype and genotype in patients with post-polycythemia Vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018;8:89.","journal-title":"Blood Cancer J"},{"key":"4253_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3324\/haematol.2016.149559","volume":"102","author":"HL Geyer","year":"2017","unstructured":"Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, et al. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL international working group. Haematologica. 2017;102:85\u201393.","journal-title":"Haematologica"},{"key":"4253_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-023-00972-x","volume":"14","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Al-Kali A, Begna KH, Elliott MA, Wolanskyj-Spinner AP, et al. One thousand patients with essential thrombocythemia: the Mayo clinic experience. Blood Cancer J. 2024;14:11.","journal-title":"Blood Cancer J"},{"key":"4253_CR23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larr\u00e1n","year":"2012","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hern\u00e1ndez-Boluda JC, Ferrer-Mar\u00edn F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia Vera. Blood. 2012;119:1363\u20139.","journal-title":"Blood"},{"key":"4253_CR24","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.3390\/cancers14184485","volume":"14","author":"TY Kim","year":"2022","unstructured":"Kim TY, Kwag D, Lee JH, Lee J, Min GJ, Park SS et al. Clinical Features, gene Alterations, and outcomes in prefibrotic and overt primary and secondary myelofibrotic patients. Cancers (Basel). 2022; 14:4485.","journal-title":"Cancers (Basel)"},{"key":"4253_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","volume":"115","author":"K Hussein","year":"2010","unstructured":"Hussein K, Pardanani AD, Van Dyke DL, Hanson CA. Tefferi. International prognostic scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115:496\u20139.","journal-title":"Blood"},{"key":"4253_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1365-2141.2005.05517.x","volume":"129","author":"PL Johansson","year":"2005","unstructured":"Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia Vera and apparent polycythaemia. Br J Haematol. 2005;129:701\u20135.","journal-title":"Br J Haematol"},{"key":"4253_CR27","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1038\/bcj.2015.64","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J. 2015;5:e337.","journal-title":"Blood Cancer J"},{"key":"4253_CR28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/leu.2013.380","volume":"28","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia Vera. Leukemia. 2014;28:1191\u20135.","journal-title":"Leukemia"},{"key":"4253_CR29","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00277-018-3344-3","volume":"97","author":"L Jakovic","year":"2018","unstructured":"Jakovic L, Gotic M, Gisslinger H, Soldatovic I, Sefer D, Tirnanic M, et al. The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin\/hematocrit level and morphology. Ann Hematol. 2018;97:1581\u201390.","journal-title":"Ann Hematol"},{"key":"4253_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15.","journal-title":"Blood Cancer J"},{"key":"4253_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11899-009-0005-6","volume":"4","author":"J Thiele","year":"2009","unstructured":"Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep. 2009;4:33\u201340.","journal-title":"Curr Hematol Malig Rep"},{"key":"4253_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41568-024-00680-z","volume":"24","author":"T Xiao","year":"2024","unstructured":"Xiao T, Lee J, Gauntner TD, Velegraki M, Lathia JD, Li Z. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. Nat Rev Cancer. 2024;24:338\u201355.","journal-title":"Nat Rev Cancer"},{"key":"4253_CR33","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3324\/haematol.2020.249441","volume":"106","author":"I Veletic","year":"2021","unstructured":"Veletic I, Prijic S, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S. Estrov. Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica. 2021;106:2384\u201396.","journal-title":"Haematologica"},{"key":"4253_CR34","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C M\u00fcller","year":"2012","unstructured":"M\u00fcller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276\u201384.","journal-title":"Blood"},{"key":"4253_CR35","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/009127009803801103","volume":"38","author":"C Tran","year":"1998","unstructured":"Tran C, Knowles SR, Liu BA. Shear. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38:1003\u20139.","journal-title":"J Clin Pharmacol"},{"key":"4253_CR36","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70\u2009+\u2009Version 2.0: mutation and Karyotype-Enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769\u201370.","journal-title":"J Clin Oncol"},{"key":"4253_CR37","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/cancers12040934","volume":"12","author":"A Segura-D\u00edaz","year":"2020","unstructured":"Segura-D\u00edaz A, Stuckey R, Florido Y, Gonz\u00e1lez-Mart\u00edn JM, L\u00f3pez-Rodr\u00edguez JF, S\u00e1nchez-Sosa S et al. Thrombotic risk detection in patients with polycythemia vera: the predictive role of DNMT3A\/TET2\/ASXL1 mutations. Cancers (Basel). 2020; 12:934.","journal-title":"Cancers (Basel)"},{"key":"4253_CR38","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"4253_CR39","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/leu.2014.76","volume":"28","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28:1804\u201310.","journal-title":"Leukemia"},{"key":"4253_CR40","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465\u201387.","journal-title":"Am J Hematol"},{"key":"4253_CR41","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99:697\u2013718.","journal-title":"Am J Hematol"},{"key":"4253_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023; 98:166\u201379.","journal-title":"Am J Hematol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04253-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04253-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04253-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:03:08Z","timestamp":1769173388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04253-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4253"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04253-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the data were de-identified and available to the public, the current study did not require ethics committee permission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}